株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ハウスダストダニアレルギー : パイプライン分析

House Dust Mite Allergy - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 246018
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
ハウスダストダニアレルギー : パイプライン分析 House Dust Mite Allergy - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 59 Pages
概要

ハウスダストダニアレルギーとは一般にハウスダストの中に生息する小さな虫に対する アレルギー反応であり、くしゃみや鼻水、鼻詰まり、鼻のかゆみ、目の痛みなどの症状があります。喘息や湿疹などの引き金になる可能性もあり、巻き上げられたハウスダストに近づくと悪化する場合があります。家族歴や年齢などが素因となり、治療法には抗ヒスタミン剤、充血緩和剤、コルチコステロイドの利用などがあります。

当レポートでは、世界におけるハウスダストダニアレルギー治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ハウスダストダニアレルギーの概要

治療薬の開発

  • ハウスダストダニアレルギー向けパイプライン製品:概要
  • ハウスダストダニアレルギー向けパイプライン製品:比較分析

ハウスダストダニアレルギー:開発中の治療薬:企業別

ハウスダストダニアレルギー:開発中の治療薬:大学・研究機関別

ハウスダストダニアレルギー:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ハウスダストダニアレルギー:開発中の製品:企業別

ハウスダストダニアレルギー:開発中の製品:大学・研究機関別

ハウスダストダニアレルギー:治療薬開発に従事している企業

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.

ハウスダストダニアレルギー:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AllerDM
  • Allergen for House Dust Mite Allergy
  • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
  • BM-35
  • MK-8237
  • PL-103
  • STG-320
  • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for House Dust Mite Allergy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • House Dust Mite Allergy - Pipeline by ALK-Abello AS, H2 2019
  • House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H2 2019
  • House Dust Mite Allergy - Pipeline by Anergis SA, H2 2019
  • House Dust Mite Allergy - Pipeline by ASIT Biotech SA, H2 2019
  • House Dust Mite Allergy - Pipeline by Astellas Pharma Inc, H2 2019
  • House Dust Mite Allergy - Pipeline by Biomay AG, H2 2019
  • House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, H2 2019
  • House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, H2 2019
  • House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H2 2019
  • House Dust Mite Allergy - Dormant Projects, H2 2019
  • House Dust Mite Allergy - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for House Dust Mite Allergy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11386IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 1, 4 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • House Dust Mite Allergy - Overview
    • House Dust Mite Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • House Dust Mite Allergy - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • House Dust Mite Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello AS
    • Allergy Therapeutics Plc
    • Anergis SA
    • ASIT Biotech SA
    • Astellas Pharma Inc
    • Biomay AG
    • Genetic Immunity Inc
    • Roxall Medizin GmbH
    • Stallergenes Greer plc
  • House Dust Mite Allergy - Drug Profiles
    • Allergan for Dust Mite Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Asthma and House Dust Mite Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-2390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-35 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clustoid d. pteronyssinus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DermAll-HDM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hdm-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for House Dust Mite Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • House Dust Mite Allergy - Dormant Projects
  • House Dust Mite Allergy - Discontinued Products
  • House Dust Mite Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears
      • May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial
      • Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint
      • May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
      • Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
      • Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
      • Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
      • Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
      • Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
      • Nov 23, 2017: European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates
      • Oct 24, 2017: ASIT biotech Publishes the Results of The hdm-ASIT+ Phase I/II Follow-up Study in House Dust Mite Rhinitis
      • Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
      • Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada
      • Aug 16, 2017: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/Iia Clinical Trial with its hdm-ASIT Product Candidate for House Dust Mite Rhinitis
      • Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top